AIP
ABBV icon

Arrowpoint Investment Partners’s AbbVie ABBV Stock Holding History

Arrowpoint Investment Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,800
Closed -$2.04M – 106
2025
Q3 		$2.04M Buy
+8,800
New +$1.79M 2.04% 13

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Arrowpoint Investment Partners's ABBV Position: Q2 2026 in Review

Arrowpoint Investment Partners opened a new position in AbbVie (ABBV) in Q2 2026: 11,928 shares worth $3M. The stake represents 0.65% of the portfolio and ranks #30 among its holdings. This is a return to the name: Arrowpoint Investment Partners previously reported a position in ABBV as recently as Q4 2025.

Arrowpoint Investment Partners first reported a position in ABBV in Q4 2025 and has held it in 2 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Arrowpoint Investment Partners held 11,928 shares of AbbVie worth $3M as of Q2 2026.
  • AbbVie was a new Arrowpoint Investment Partners position in Q2 2026.
  • AbbVie made up 0.65% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #30 holding.
  • Arrowpoint Investment Partners first reported a position in AbbVie in Q4 2025 and has held it in 2 quarters since.
  • 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.